nodes	percent_of_prediction	percent_of_DWPC	metapath
Pimecrolimus—MTOR—hindlimb—muscle cancer	0.0715	0.214	CbGeAlD
Pimecrolimus—MTOR—appendage—muscle cancer	0.0613	0.183	CbGeAlD
Pimecrolimus—Other conjunctivitis—Doxorubicin—muscle cancer	0.0391	0.117	CcSEcCtD
Pimecrolimus—FKBP1A—TGF-beta Receptor Signaling—TFE3—muscle cancer	0.0267	0.0807	CbGpPWpGaD
Pimecrolimus—MTOR—embryo—muscle cancer	0.0204	0.0609	CbGeAlD
Pimecrolimus—Leukaemia—Vincristine—muscle cancer	0.0166	0.0495	CcSEcCtD
Pimecrolimus—MTOR—smooth muscle tissue—muscle cancer	0.016	0.0479	CbGeAlD
Pimecrolimus—MTOR—renal system—muscle cancer	0.0154	0.0461	CbGeAlD
Pimecrolimus—FKBP1A—smooth muscle tissue—muscle cancer	0.0144	0.043	CbGeAlD
Pimecrolimus—FKBP1A—renal system—muscle cancer	0.0139	0.0414	CbGeAlD
Pimecrolimus—FKBP1A—cardiac atrium—muscle cancer	0.0124	0.0371	CbGeAlD
Pimecrolimus—MTOR—tendon—muscle cancer	0.012	0.036	CbGeAlD
Pimecrolimus—MTOR—bone marrow—muscle cancer	0.0117	0.0348	CbGeAlD
Pimecrolimus—MTOR—vagina—muscle cancer	0.0112	0.0334	CbGeAlD
Pimecrolimus—FKBP1A—tendon—muscle cancer	0.0108	0.0323	CbGeAlD
Pimecrolimus—FKBP1A—bone marrow—muscle cancer	0.0105	0.0313	CbGeAlD
Pimecrolimus—MTOR—head—muscle cancer	0.0103	0.0308	CbGeAlD
Pimecrolimus—FKBP1A—vagina—muscle cancer	0.01	0.03	CbGeAlD
Pimecrolimus—MTOR—testis—muscle cancer	0.00996	0.0298	CbGeAlD
Pimecrolimus—FKBP1A—head—muscle cancer	0.00928	0.0277	CbGeAlD
Pimecrolimus—FKBP1A—testis—muscle cancer	0.00896	0.0268	CbGeAlD
Pimecrolimus—Leukaemia—Methotrexate—muscle cancer	0.00803	0.024	CcSEcCtD
Pimecrolimus—MTOR—Class I PI3K signaling events mediated by Akt—FOXO4—muscle cancer	0.00794	0.024	CbGpPWpGaD
Pimecrolimus—Folliculitis—Dactinomycin—muscle cancer	0.00794	0.0237	CcSEcCtD
Pimecrolimus—MTOR—BDNF signaling pathway—KIDINS220—muscle cancer	0.00757	0.0229	CbGpPWpGaD
Pimecrolimus—MTOR—FSH signaling pathway—FOXO1—muscle cancer	0.00722	0.0218	CbGpPWpGaD
Pimecrolimus—FKBP1A—Calcium signaling in the CD4+ TCR pathway—PTGS2—muscle cancer	0.00701	0.0212	CbGpPWpGaD
Pimecrolimus—Leukaemia—Doxorubicin—muscle cancer	0.00696	0.0208	CcSEcCtD
Pimecrolimus—MTOR—Regulation of Telomerase—WT1—muscle cancer	0.00639	0.0193	CbGpPWpGaD
Pimecrolimus—Lymphoma—Methotrexate—muscle cancer	0.00619	0.0185	CcSEcCtD
Pimecrolimus—MTOR—Class I PI3K signaling events mediated by Akt—FOXO1—muscle cancer	0.00587	0.0177	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—KIDINS220—muscle cancer	0.00568	0.0172	CbGpPWpGaD
Pimecrolimus—MTOR—IL4-mediated signaling events—HMGA1—muscle cancer	0.00561	0.017	CbGpPWpGaD
Pimecrolimus—Sensitisation—Doxorubicin—muscle cancer	0.00525	0.0157	CcSEcCtD
Pimecrolimus—Leukoderma—Methotrexate—muscle cancer	0.00509	0.0152	CcSEcCtD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—WT1—muscle cancer	0.00497	0.015	CbGpPWpGaD
Pimecrolimus—Bacterial infection—Methotrexate—muscle cancer	0.00469	0.014	CcSEcCtD
Pimecrolimus—CYP3A4—renal system—muscle cancer	0.00453	0.0135	CbGeAlD
Pimecrolimus—Furuncle—Methotrexate—muscle cancer	0.00441	0.0132	CcSEcCtD
Pimecrolimus—Leukoderma—Doxorubicin—muscle cancer	0.00441	0.0132	CcSEcCtD
Pimecrolimus—MTOR—Signaling by NGF—KIDINS220—muscle cancer	0.00437	0.0132	CbGpPWpGaD
Pimecrolimus—MTOR—ErbB Signaling Pathway—FOXO1—muscle cancer	0.00415	0.0125	CbGpPWpGaD
Pimecrolimus—Skin discolouration—Etoposide—muscle cancer	0.004	0.0119	CcSEcCtD
Pimecrolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—FOXO4—muscle cancer	0.00387	0.0117	CbGpPWpGaD
Pimecrolimus—Furuncle—Doxorubicin—muscle cancer	0.00382	0.0114	CcSEcCtD
Pimecrolimus—MTOR—Senescence and Autophagy in Cancer—HMGA1—muscle cancer	0.00368	0.0111	CbGpPWpGaD
Pimecrolimus—Skin hyperpigmentation—Methotrexate—muscle cancer	0.00364	0.0109	CcSEcCtD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	0.00363	0.011	CbGpPWpGaD
Pimecrolimus—MTOR—PI-3K cascade—FOXO4—muscle cancer	0.00349	0.0105	CbGpPWpGaD
Pimecrolimus—Skin exfoliation—Etoposide—muscle cancer	0.00345	0.0103	CcSEcCtD
Pimecrolimus—Folliculitis—Methotrexate—muscle cancer	0.00344	0.0103	CcSEcCtD
Pimecrolimus—MTOR—PI3K/AKT activation—FOXO4—muscle cancer	0.0034	0.0103	CbGpPWpGaD
Pimecrolimus—MTOR—GAB1 signalosome—FOXO4—muscle cancer	0.00338	0.0102	CbGpPWpGaD
Pimecrolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—FOXO4—muscle cancer	0.0033	0.00997	CbGpPWpGaD
Pimecrolimus—MTOR—Leptin signaling pathway—FOXO1—muscle cancer	0.00319	0.00964	CbGpPWpGaD
Pimecrolimus—Skin hyperpigmentation—Doxorubicin—muscle cancer	0.00315	0.00941	CcSEcCtD
Pimecrolimus—MTOR—IRS-related events triggered by IGF1R—IGF2—muscle cancer	0.00302	0.00914	CbGpPWpGaD
Pimecrolimus—Folliculitis—Doxorubicin—muscle cancer	0.00298	0.00891	CcSEcCtD
Pimecrolimus—Swelling—Etoposide—muscle cancer	0.00297	0.00888	CcSEcCtD
Pimecrolimus—MTOR—IGF1R signaling cascade—IGF2—muscle cancer	0.00294	0.0089	CbGpPWpGaD
Pimecrolimus—MTOR—CXCR4-mediated signaling events—FOXO1—muscle cancer	0.00291	0.00881	CbGpPWpGaD
Pimecrolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—FOXO1—muscle cancer	0.00286	0.00864	CbGpPWpGaD
Pimecrolimus—Pneumonia—Dactinomycin—muscle cancer	0.00281	0.00839	CcSEcCtD
Pimecrolimus—MTOR—Signaling by SCF-KIT—FOXO4—muscle cancer	0.00261	0.00788	CbGpPWpGaD
Pimecrolimus—MTOR—PI-3K cascade—FOXO1—muscle cancer	0.00257	0.00778	CbGpPWpGaD
Pimecrolimus—Photosensitivity reaction—Vincristine—muscle cancer	0.00255	0.00763	CcSEcCtD
Pimecrolimus—MTOR—BDNF signaling pathway—CNR1—muscle cancer	0.00251	0.0076	CbGpPWpGaD
Pimecrolimus—MTOR—PI3K/AKT activation—FOXO1—muscle cancer	0.00251	0.0076	CbGpPWpGaD
Pimecrolimus—Pneumonia—Vincristine—muscle cancer	0.00251	0.0075	CcSEcCtD
Pimecrolimus—MTOR—GAB1 signalosome—FOXO1—muscle cancer	0.00249	0.00754	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—FOXO4—muscle cancer	0.00249	0.00754	CbGpPWpGaD
Pimecrolimus—MTOR—ErbB Signaling Pathway—MDM2—muscle cancer	0.00249	0.00753	CbGpPWpGaD
Pimecrolimus—Pharyngitis—Dactinomycin—muscle cancer	0.00249	0.00743	CcSEcCtD
Pimecrolimus—MTOR—Signaling by ERBB4—FOXO4—muscle cancer	0.00245	0.00742	CbGpPWpGaD
Pimecrolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—FOXO1—muscle cancer	0.00244	0.00737	CbGpPWpGaD
Pimecrolimus—Otitis media—Doxorubicin—muscle cancer	0.00241	0.00719	CcSEcCtD
Pimecrolimus—Skin discolouration—Methotrexate—muscle cancer	0.0024	0.00716	CcSEcCtD
Pimecrolimus—Bone disorder—Methotrexate—muscle cancer	0.0024	0.00716	CcSEcCtD
Pimecrolimus—Herpes simplex—Methotrexate—muscle cancer	0.00235	0.00701	CcSEcCtD
Pimecrolimus—MTOR—Downstream signal transduction—FOXO4—muscle cancer	0.00234	0.00709	CbGpPWpGaD
Pimecrolimus—MTOR—EGF/EGFR Signaling Pathway—FOXO4—muscle cancer	0.00233	0.00705	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—FOXO4—muscle cancer	0.00233	0.00705	CbGpPWpGaD
Pimecrolimus—Flushing—Dactinomycin—muscle cancer	0.00233	0.00695	CcSEcCtD
Pimecrolimus—MTOR—Signaling by ERBB2—FOXO4—muscle cancer	0.00232	0.00702	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—FOXO4—muscle cancer	0.00231	0.00698	CbGpPWpGaD
Pimecrolimus—FKBP1A—Spinal Cord Injury—PTGS2—muscle cancer	0.00228	0.0069	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—FOXO4—muscle cancer	0.00228	0.00688	CbGpPWpGaD
Pimecrolimus—Neoplasm malignant—Doxorubicin—muscle cancer	0.00219	0.00655	CcSEcCtD
Pimecrolimus—Erythema—Dactinomycin—muscle cancer	0.00218	0.00652	CcSEcCtD
Pimecrolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—KIT—muscle cancer	0.00218	0.00658	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—FOXO4—muscle cancer	0.00217	0.00657	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—FOXO4—muscle cancer	0.00217	0.00657	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—FOXO4—muscle cancer	0.00217	0.00657	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—FOXO4—muscle cancer	0.00215	0.00651	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—FOXO4—muscle cancer	0.00213	0.00645	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—FOXO4—muscle cancer	0.00212	0.00642	CbGpPWpGaD
Pimecrolimus—Viral infection—Doxorubicin—muscle cancer	0.00207	0.0062	CcSEcCtD
Pimecrolimus—Skin discolouration—Doxorubicin—muscle cancer	0.00207	0.0062	CcSEcCtD
Pimecrolimus—Bone disorder—Doxorubicin—muscle cancer	0.00207	0.0062	CcSEcCtD
Pimecrolimus—Skin exfoliation—Methotrexate—muscle cancer	0.00207	0.00617	CcSEcCtD
Pimecrolimus—Herpes simplex—Doxorubicin—muscle cancer	0.00203	0.00607	CcSEcCtD
Pimecrolimus—Pneumonia—Etoposide—muscle cancer	0.00203	0.00607	CcSEcCtD
Pimecrolimus—Infestation—Etoposide—muscle cancer	0.00202	0.00604	CcSEcCtD
Pimecrolimus—Infestation NOS—Etoposide—muscle cancer	0.00202	0.00604	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Vincristine—muscle cancer	0.00202	0.00603	CcSEcCtD
Pimecrolimus—MTOR—B Cell Activation—FOXO4—muscle cancer	0.00201	0.00608	CbGpPWpGaD
Pimecrolimus—MTOR—PI-3K cascade—KIT—muscle cancer	0.00196	0.00593	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by SCF-KIT—FOXO1—muscle cancer	0.00192	0.00582	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—FOXO4—muscle cancer	0.00192	0.00582	CbGpPWpGaD
Pimecrolimus—MTOR—PI3K/AKT activation—KIT—muscle cancer	0.00191	0.00579	CbGpPWpGaD
Pimecrolimus—MTOR—GAB1 signalosome—KIT—muscle cancer	0.0019	0.00574	CbGpPWpGaD
Pimecrolimus—Back pain—Vincristine—muscle cancer	0.00189	0.00563	CcSEcCtD
Pimecrolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—KIT—muscle cancer	0.00186	0.00561	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—FOXO1—muscle cancer	0.00184	0.00557	CbGpPWpGaD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—FOXO1—muscle cancer	0.00182	0.00551	CbGpPWpGaD
Pimecrolimus—Influenza like illness—Doxorubicin—muscle cancer	0.00182	0.00544	CcSEcCtD
Pimecrolimus—MTOR—Signaling by ERBB4—FOXO1—muscle cancer	0.00181	0.00548	CbGpPWpGaD
Pimecrolimus—Skin exfoliation—Doxorubicin—muscle cancer	0.00179	0.00534	CcSEcCtD
Pimecrolimus—Oedema—Dactinomycin—muscle cancer	0.00178	0.00532	CcSEcCtD
Pimecrolimus—Infection—Dactinomycin—muscle cancer	0.00177	0.00529	CcSEcCtD
Pimecrolimus—MTOR—Cellular responses to stress—HMGA1—muscle cancer	0.00176	0.00532	CbGpPWpGaD
Pimecrolimus—MTOR—Insulin Signaling—FOXO1—muscle cancer	0.00174	0.00526	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signal transduction—FOXO1—muscle cancer	0.00173	0.00523	CbGpPWpGaD
Pimecrolimus—MTOR—EGF/EGFR Signaling Pathway—FOXO1—muscle cancer	0.00172	0.00521	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—FOXO1—muscle cancer	0.00172	0.00521	CbGpPWpGaD
Pimecrolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—MDM2—muscle cancer	0.00172	0.00519	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB2—FOXO1—muscle cancer	0.00171	0.00518	CbGpPWpGaD
Pimecrolimus—MTOR—LKB1 signaling events—TP53—muscle cancer	0.00171	0.00518	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—FOXO1—muscle cancer	0.00171	0.00516	CbGpPWpGaD
Pimecrolimus—Eye disorder—Etoposide—muscle cancer	0.0017	0.00506	CcSEcCtD
Pimecrolimus—Flushing—Etoposide—muscle cancer	0.00168	0.00503	CcSEcCtD
Pimecrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—FOXO1—muscle cancer	0.00168	0.00508	CbGpPWpGaD
Pimecrolimus—CYP3A4—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	0.00167	0.00506	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—KIDINS220—muscle cancer	0.00167	0.00505	CbGpPWpGaD
Pimecrolimus—Dermatitis exfoliative—Methotrexate—muscle cancer	0.00166	0.00497	CcSEcCtD
Pimecrolimus—Immune system disorder—Etoposide—muscle cancer	0.00164	0.0049	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Etoposide—muscle cancer	0.00163	0.00488	CcSEcCtD
Pimecrolimus—MTOR—Oncostatin M Signaling Pathway—VEGFA—muscle cancer	0.00163	0.00493	CbGpPWpGaD
Pimecrolimus—Musculoskeletal discomfort—Dactinomycin—muscle cancer	0.00162	0.00485	CcSEcCtD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	0.00161	0.00487	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—FOXO1—muscle cancer	0.0016	0.00485	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—FOXO1—muscle cancer	0.0016	0.00485	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—FOXO1—muscle cancer	0.0016	0.00485	CbGpPWpGaD
Pimecrolimus—Anaphylactic shock—Vincristine—muscle cancer	0.00159	0.00475	CcSEcCtD
Pimecrolimus—Oedema—Vincristine—muscle cancer	0.00159	0.00475	CcSEcCtD
Pimecrolimus—MTOR—Signaling by EGFR—FOXO1—muscle cancer	0.00159	0.00481	CbGpPWpGaD
Pimecrolimus—Infection—Vincristine—muscle cancer	0.00158	0.00472	CcSEcCtD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—FOXO1—muscle cancer	0.00158	0.00477	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—FOXO1—muscle cancer	0.00157	0.00474	CbGpPWpGaD
Pimecrolimus—Nervous system disorder—Vincristine—muscle cancer	0.00156	0.00466	CcSEcCtD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	0.00155	0.0047	CbGpPWpGaD
Pimecrolimus—MTOR—PI-3K cascade—MDM2—muscle cancer	0.00154	0.00467	CbGpPWpGaD
Pimecrolimus—Back pain—Etoposide—muscle cancer	0.00153	0.00456	CcSEcCtD
Pimecrolimus—Pain—Dactinomycin—muscle cancer	0.00152	0.00455	CcSEcCtD
Pimecrolimus—MTOR—PI3K/AKT activation—MDM2—muscle cancer	0.00151	0.00456	CbGpPWpGaD
Pimecrolimus—MTOR—Senescence and Autophagy in Cancer—CDKN2A—muscle cancer	0.00151	0.00456	CbGpPWpGaD
Pimecrolimus—MTOR—GAB1 signalosome—MDM2—muscle cancer	0.0015	0.00452	CbGpPWpGaD
Pimecrolimus—MTOR—B Cell Activation—FOXO1—muscle cancer	0.00148	0.00449	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—FOXO4—muscle cancer	0.00148	0.00447	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by SCF-KIT—KIT—muscle cancer	0.00147	0.00443	CbGpPWpGaD
Pimecrolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—MDM2—muscle cancer	0.00146	0.00442	CbGpPWpGaD
Pimecrolimus—MTOR—Senescence and Autophagy in Cancer—MDM2—muscle cancer	0.00146	0.00442	CbGpPWpGaD
Pimecrolimus—Gastrointestinal pain—Dactinomycin—muscle cancer	0.00146	0.00435	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Vincristine—muscle cancer	0.00145	0.00433	CcSEcCtD
Pimecrolimus—Dermatitis exfoliative—Doxorubicin—muscle cancer	0.00144	0.00431	CcSEcCtD
Pimecrolimus—Paraesthesia—Vincristine—muscle cancer	0.00143	0.00427	CcSEcCtD
Pimecrolimus—MTOR—ErbB Signaling Pathway—TP53—muscle cancer	0.00143	0.00432	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—FOXO1—muscle cancer	0.00142	0.0043	CbGpPWpGaD
Pimecrolimus—Breast disorder—Methotrexate—muscle cancer	0.00142	0.00424	CcSEcCtD
Pimecrolimus—Abdominal pain—Dactinomycin—muscle cancer	0.00141	0.00421	CcSEcCtD
Pimecrolimus—Body temperature increased—Dactinomycin—muscle cancer	0.00141	0.00421	CcSEcCtD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—KIT—muscle cancer	0.0014	0.00424	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB4—KIT—muscle cancer	0.00138	0.00418	CbGpPWpGaD
Pimecrolimus—Cough—Etoposide—muscle cancer	0.00138	0.00412	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Vincristine—muscle cancer	0.00137	0.0041	CcSEcCtD
Pimecrolimus—Pain—Vincristine—muscle cancer	0.00136	0.00406	CcSEcCtD
Pimecrolimus—Constipation—Vincristine—muscle cancer	0.00136	0.00406	CcSEcCtD
Pimecrolimus—FKBP1A—Spinal Cord Injury—TP53—muscle cancer	0.00136	0.00411	CbGpPWpGaD
Pimecrolimus—Asthma—Methotrexate—muscle cancer	0.00136	0.00406	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	0.00134	0.00399	CcSEcCtD
Pimecrolimus—MTOR—Downstream signal transduction—KIT—muscle cancer	0.00132	0.00399	CbGpPWpGaD
Pimecrolimus—Face oedema—Doxorubicin—muscle cancer	0.00131	0.00392	CcSEcCtD
Pimecrolimus—MTOR—Signaling by FGFR—KIT—muscle cancer	0.00131	0.00397	CbGpPWpGaD
Pimecrolimus—Hypersensitivity—Dactinomycin—muscle cancer	0.00131	0.00392	CcSEcCtD
Pimecrolimus—MTOR—Signaling by ERBB2—KIT—muscle cancer	0.00131	0.00395	CbGpPWpGaD
Pimecrolimus—Gastrointestinal pain—Vincristine—muscle cancer	0.0013	0.00389	CcSEcCtD
Pimecrolimus—MTOR—DAP12 signaling—KIT—muscle cancer	0.0013	0.00393	CbGpPWpGaD
Pimecrolimus—Anaphylactic shock—Etoposide—muscle cancer	0.00129	0.00385	CcSEcCtD
Pimecrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—KIT—muscle cancer	0.00128	0.00387	CbGpPWpGaD
Pimecrolimus—Infection—Etoposide—muscle cancer	0.00128	0.00383	CcSEcCtD
Pimecrolimus—Upper respiratory tract infection—Methotrexate—muscle cancer	0.00126	0.00377	CcSEcCtD
Pimecrolimus—Abdominal pain—Vincristine—muscle cancer	0.00126	0.00376	CcSEcCtD
Pimecrolimus—Body temperature increased—Vincristine—muscle cancer	0.00126	0.00376	CcSEcCtD
Pimecrolimus—Skin disorder—Etoposide—muscle cancer	0.00125	0.00374	CcSEcCtD
Pimecrolimus—Abdominal pain upper—Doxorubicin—muscle cancer	0.00124	0.00371	CcSEcCtD
Pimecrolimus—Photosensitivity reaction—Methotrexate—muscle cancer	0.00124	0.0037	CcSEcCtD
Pimecrolimus—MTOR—Oncostatin M Signaling Pathway—TP53—muscle cancer	0.00123	0.00372	CbGpPWpGaD
Pimecrolimus—Breast disorder—Doxorubicin—muscle cancer	0.00123	0.00367	CcSEcCtD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	0.00122	0.0037	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—KIT—muscle cancer	0.00122	0.0037	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—KIT—muscle cancer	0.00122	0.0037	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—KIT—muscle cancer	0.00122	0.0037	CbGpPWpGaD
Pimecrolimus—Diarrhoea—Dactinomycin—muscle cancer	0.00122	0.00364	CcSEcCtD
Pimecrolimus—Pneumonia—Methotrexate—muscle cancer	0.00122	0.00364	CcSEcCtD
Pimecrolimus—Nasopharyngitis—Doxorubicin—muscle cancer	0.00122	0.00363	CcSEcCtD
Pimecrolimus—MTOR—Signaling by EGFR—KIT—muscle cancer	0.00121	0.00366	CbGpPWpGaD
Pimecrolimus—Infestation NOS—Methotrexate—muscle cancer	0.00121	0.00362	CcSEcCtD
Pimecrolimus—Infestation—Methotrexate—muscle cancer	0.00121	0.00362	CcSEcCtD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—KIT—muscle cancer	0.0012	0.00363	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—KIT—muscle cancer	0.0012	0.00361	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—CD34—muscle cancer	0.00119	0.00361	CbGpPWpGaD
Pimecrolimus—Conjunctivitis—Methotrexate—muscle cancer	0.00118	0.00351	CcSEcCtD
Pimecrolimus—Influenza—Doxorubicin—muscle cancer	0.00118	0.00351	CcSEcCtD
Pimecrolimus—Asthma—Doxorubicin—muscle cancer	0.00118	0.00351	CcSEcCtD
Pimecrolimus—MTOR—AMPK Signaling—TP53—muscle cancer	0.00117	0.00355	CbGpPWpGaD
Pimecrolimus—Hypersensitivity—Vincristine—muscle cancer	0.00117	0.0035	CcSEcCtD
Pimecrolimus—Paraesthesia—Etoposide—muscle cancer	0.00116	0.00346	CcSEcCtD
Pimecrolimus—MTOR—Signaling by SCF-KIT—MDM2—muscle cancer	0.00115	0.00349	CbGpPWpGaD
Pimecrolimus—Dyspnoea—Etoposide—muscle cancer	0.00115	0.00343	CcSEcCtD
Pimecrolimus—Epistaxis—Methotrexate—muscle cancer	0.00114	0.00341	CcSEcCtD
Pimecrolimus—Vomiting—Dactinomycin—muscle cancer	0.00113	0.00338	CcSEcCtD
Pimecrolimus—MTOR—B Cell Activation—KIT—muscle cancer	0.00113	0.00342	CbGpPWpGaD
Pimecrolimus—Bronchitis—Doxorubicin—muscle cancer	0.00113	0.00338	CcSEcCtD
Pimecrolimus—Rash—Dactinomycin—muscle cancer	0.00112	0.00335	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Etoposide—muscle cancer	0.00111	0.00332	CcSEcCtD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—MDM2—muscle cancer	0.0011	0.00334	CbGpPWpGaD
Pimecrolimus—Pain—Etoposide—muscle cancer	0.0011	0.00329	CcSEcCtD
Pimecrolimus—Constipation—Etoposide—muscle cancer	0.0011	0.00329	CcSEcCtD
Pimecrolimus—MTOR—VEGFA-VEGFR2 Pathway—VEGFA—muscle cancer	0.00109	0.00331	CbGpPWpGaD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—MDM2—muscle cancer	0.00109	0.00331	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—FOXO1—muscle cancer	0.00109	0.0033	CbGpPWpGaD
Pimecrolimus—Upper respiratory tract infection—Doxorubicin—muscle cancer	0.00109	0.00326	CcSEcCtD
Pimecrolimus—Diarrhoea—Vincristine—muscle cancer	0.00109	0.00325	CcSEcCtD
Pimecrolimus—MTOR—Signaling by ERBB4—MDM2—muscle cancer	0.00109	0.00329	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—KIT—muscle cancer	0.00108	0.00327	CbGpPWpGaD
Pimecrolimus—Pharyngitis—Methotrexate—muscle cancer	0.00108	0.00322	CcSEcCtD
Pimecrolimus—Photosensitivity reaction—Doxorubicin—muscle cancer	0.00107	0.00321	CcSEcCtD
Pimecrolimus—Nausea—Dactinomycin—muscle cancer	0.00106	0.00316	CcSEcCtD
Pimecrolimus—Pneumonia—Doxorubicin—muscle cancer	0.00105	0.00315	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Etoposide—muscle cancer	0.00105	0.00315	CcSEcCtD
Pimecrolimus—Infestation NOS—Doxorubicin—muscle cancer	0.00105	0.00313	CcSEcCtD
Pimecrolimus—Infestation—Doxorubicin—muscle cancer	0.00105	0.00313	CcSEcCtD
Pimecrolimus—MTOR—Downstream signal transduction—MDM2—muscle cancer	0.00104	0.00314	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—MDM2—muscle cancer	0.00103	0.00312	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by VEGF—VEGFA—muscle cancer	0.00103	0.00312	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB2—MDM2—muscle cancer	0.00103	0.00311	CbGpPWpGaD
Pimecrolimus—Urticaria—Etoposide—muscle cancer	0.00102	0.00306	CcSEcCtD
Pimecrolimus—MTOR—DAP12 signaling—MDM2—muscle cancer	0.00102	0.00309	CbGpPWpGaD
Pimecrolimus—Body temperature increased—Etoposide—muscle cancer	0.00102	0.00304	CcSEcCtD
Pimecrolimus—Abdominal pain—Etoposide—muscle cancer	0.00102	0.00304	CcSEcCtD
Pimecrolimus—Conjunctivitis—Doxorubicin—muscle cancer	0.00102	0.00304	CcSEcCtD
Pimecrolimus—Eye disorder—Methotrexate—muscle cancer	0.00102	0.00303	CcSEcCtD
Pimecrolimus—Vomiting—Vincristine—muscle cancer	0.00101	0.00302	CcSEcCtD
Pimecrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—MDM2—muscle cancer	0.00101	0.00305	CbGpPWpGaD
Pimecrolimus—Rash—Vincristine—muscle cancer	0.001	0.003	CcSEcCtD
Pimecrolimus—Dermatitis—Vincristine—muscle cancer	0.001	0.00299	CcSEcCtD
Pimecrolimus—Headache—Vincristine—muscle cancer	0.000997	0.00298	CcSEcCtD
Pimecrolimus—FKBP1A—Disease—ENO2—muscle cancer	0.00099	0.00299	CbGpPWpGaD
Pimecrolimus—Epistaxis—Doxorubicin—muscle cancer	0.000989	0.00295	CcSEcCtD
Pimecrolimus—Sinusitis—Doxorubicin—muscle cancer	0.000983	0.00294	CcSEcCtD
Pimecrolimus—Immune system disorder—Methotrexate—muscle cancer	0.000981	0.00293	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Methotrexate—muscle cancer	0.000979	0.00293	CcSEcCtD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—MDM2—muscle cancer	0.000963	0.00291	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—MDM2—muscle cancer	0.000963	0.00291	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—MDM2—muscle cancer	0.000963	0.00291	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—MDM2—muscle cancer	0.000954	0.00289	CbGpPWpGaD
Pimecrolimus—Hypersensitivity—Etoposide—muscle cancer	0.00095	0.00284	CcSEcCtD
Pimecrolimus—Malnutrition—Methotrexate—muscle cancer	0.000946	0.00283	CcSEcCtD
Pimecrolimus—Erythema—Methotrexate—muscle cancer	0.000946	0.00283	CcSEcCtD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—MDM2—muscle cancer	0.000946	0.00286	CbGpPWpGaD
Pimecrolimus—Nausea—Vincristine—muscle cancer	0.000945	0.00282	CcSEcCtD
Pimecrolimus—Rhinitis—Doxorubicin—muscle cancer	0.000943	0.00282	CcSEcCtD
Pimecrolimus—MTOR—Signaling by PDGF—MDM2—muscle cancer	0.000941	0.00285	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—KIDINS220—muscle cancer	0.000939	0.00284	CbGpPWpGaD
Pimecrolimus—Pharyngitis—Doxorubicin—muscle cancer	0.000934	0.00279	CcSEcCtD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	0.000924	0.00279	CbGpPWpGaD
Pimecrolimus—Back pain—Methotrexate—muscle cancer	0.000915	0.00273	CcSEcCtD
Pimecrolimus—Pruritus—Etoposide—muscle cancer	0.000912	0.00272	CcSEcCtD
Pimecrolimus—FKBP1A—Disease—HMGA1—muscle cancer	0.0009	0.00272	CbGpPWpGaD
Pimecrolimus—MTOR—B Cell Activation—MDM2—muscle cancer	0.000891	0.00269	CbGpPWpGaD
Pimecrolimus—Diarrhoea—Etoposide—muscle cancer	0.000882	0.00263	CcSEcCtD
Pimecrolimus—Eye disorder—Doxorubicin—muscle cancer	0.000879	0.00263	CcSEcCtD
Pimecrolimus—Flushing—Doxorubicin—muscle cancer	0.000873	0.00261	CcSEcCtD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—MDM2—muscle cancer	0.000853	0.00258	CbGpPWpGaD
Pimecrolimus—Immune system disorder—Doxorubicin—muscle cancer	0.00085	0.00254	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Doxorubicin—muscle cancer	0.000848	0.00253	CcSEcCtD
Pimecrolimus—MTOR—Innate Immune System—FOXO4—muscle cancer	0.000844	0.00255	CbGpPWpGaD
Pimecrolimus—MTOR—Senescence and Autophagy in Cancer—TP53—muscle cancer	0.000839	0.00254	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—KIT—muscle cancer	0.000833	0.00252	CbGpPWpGaD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—VEGFA—muscle cancer	0.00083	0.00251	CbGpPWpGaD
Pimecrolimus—Cough—Methotrexate—muscle cancer	0.000825	0.00247	CcSEcCtD
Pimecrolimus—Vomiting—Etoposide—muscle cancer	0.000819	0.00245	CcSEcCtD
Pimecrolimus—Malnutrition—Doxorubicin—muscle cancer	0.000819	0.00245	CcSEcCtD
Pimecrolimus—Erythema—Doxorubicin—muscle cancer	0.000819	0.00245	CcSEcCtD
Pimecrolimus—Rash—Etoposide—muscle cancer	0.000813	0.00243	CcSEcCtD
Pimecrolimus—Dermatitis—Etoposide—muscle cancer	0.000812	0.00243	CcSEcCtD
Pimecrolimus—MTOR—Adaptive Immune System—FOXO4—muscle cancer	0.00081	0.00245	CbGpPWpGaD
Pimecrolimus—Headache—Etoposide—muscle cancer	0.000807	0.00241	CcSEcCtD
Pimecrolimus—FKBP1A—Disease—FOXO4—muscle cancer	0.000807	0.00244	CbGpPWpGaD
Pimecrolimus—Arthralgia—Methotrexate—muscle cancer	0.000805	0.00241	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	0.0008	0.00239	CcSEcCtD
Pimecrolimus—Back pain—Doxorubicin—muscle cancer	0.000792	0.00237	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Methotrexate—muscle cancer	0.000772	0.00231	CcSEcCtD
Pimecrolimus—Infection—Methotrexate—muscle cancer	0.000767	0.00229	CcSEcCtD
Pimecrolimus—Nausea—Etoposide—muscle cancer	0.000766	0.00229	CcSEcCtD
Pimecrolimus—Nervous system disorder—Methotrexate—muscle cancer	0.000757	0.00226	CcSEcCtD
Pimecrolimus—CYP3A4—Tryptophan metabolism—MDM2—muscle cancer	0.00075	0.00227	CbGpPWpGaD
Pimecrolimus—Skin disorder—Methotrexate—muscle cancer	0.00075	0.00224	CcSEcCtD
Pimecrolimus—MTOR—Immune System—CD34—muscle cancer	0.000723	0.00219	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—CDKN2A—muscle cancer	0.000721	0.00218	CbGpPWpGaD
Pimecrolimus—Cough—Doxorubicin—muscle cancer	0.000715	0.00214	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Methotrexate—muscle cancer	0.000703	0.0021	CcSEcCtD
Pimecrolimus—MTOR—Cellular responses to stress—MDM2—muscle cancer	0.000699	0.00211	CbGpPWpGaD
Pimecrolimus—Arthralgia—Doxorubicin—muscle cancer	0.000697	0.00208	CcSEcCtD
Pimecrolimus—Paraesthesia—Methotrexate—muscle cancer	0.000693	0.00207	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	0.000693	0.00207	CcSEcCtD
Pimecrolimus—Dyspnoea—Methotrexate—muscle cancer	0.000688	0.00206	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Doxorubicin—muscle cancer	0.000668	0.002	CcSEcCtD
Pimecrolimus—Oedema—Doxorubicin—muscle cancer	0.000668	0.002	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Methotrexate—muscle cancer	0.000666	0.00199	CcSEcCtD
Pimecrolimus—Infection—Doxorubicin—muscle cancer	0.000664	0.00198	CcSEcCtD
Pimecrolimus—Pain—Methotrexate—muscle cancer	0.00066	0.00197	CcSEcCtD
Pimecrolimus—FKBP1A—Signaling Pathways—PTCH1—muscle cancer	0.000657	0.00199	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—MDM2—muscle cancer	0.000656	0.00198	CbGpPWpGaD
Pimecrolimus—Nervous system disorder—Doxorubicin—muscle cancer	0.000656	0.00196	CcSEcCtD
Pimecrolimus—Skin disorder—Doxorubicin—muscle cancer	0.000649	0.00194	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Methotrexate—muscle cancer	0.000631	0.00189	CcSEcCtD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—TP53—muscle cancer	0.000627	0.0019	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—FOXO1—muscle cancer	0.000623	0.00188	CbGpPWpGaD
Pimecrolimus—Urticaria—Methotrexate—muscle cancer	0.000613	0.00183	CcSEcCtD
Pimecrolimus—Body temperature increased—Methotrexate—muscle cancer	0.00061	0.00182	CcSEcCtD
Pimecrolimus—Abdominal pain—Methotrexate—muscle cancer	0.00061	0.00182	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Doxorubicin—muscle cancer	0.000609	0.00182	CcSEcCtD
Pimecrolimus—Paraesthesia—Doxorubicin—muscle cancer	0.0006	0.00179	CcSEcCtD
Pimecrolimus—MTOR—Adaptive Immune System—FOXO1—muscle cancer	0.000599	0.00181	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—FOXO1—muscle cancer	0.000596	0.0018	CbGpPWpGaD
Pimecrolimus—Dyspnoea—Doxorubicin—muscle cancer	0.000596	0.00178	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Doxorubicin—muscle cancer	0.000577	0.00172	CcSEcCtD
Pimecrolimus—Pain—Doxorubicin—muscle cancer	0.000572	0.00171	CcSEcCtD
Pimecrolimus—Constipation—Doxorubicin—muscle cancer	0.000572	0.00171	CcSEcCtD
Pimecrolimus—Hypersensitivity—Methotrexate—muscle cancer	0.000569	0.0017	CcSEcCtD
Pimecrolimus—FKBP1A—Signaling Pathways—FOXO4—muscle cancer	0.000565	0.00171	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—ENO2—muscle cancer	0.000557	0.00168	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CNR1—muscle cancer	0.000555	0.00168	CbGpPWpGaD
Pimecrolimus—Gastrointestinal pain—Doxorubicin—muscle cancer	0.000547	0.00163	CcSEcCtD
Pimecrolimus—Pruritus—Methotrexate—muscle cancer	0.000546	0.00163	CcSEcCtD
Pimecrolimus—Urticaria—Doxorubicin—muscle cancer	0.000531	0.00159	CcSEcCtD
Pimecrolimus—MTOR—Cellular responses to stress—VEGFA—muscle cancer	0.000531	0.00161	CbGpPWpGaD
Pimecrolimus—Body temperature increased—Doxorubicin—muscle cancer	0.000528	0.00158	CcSEcCtD
Pimecrolimus—Abdominal pain—Doxorubicin—muscle cancer	0.000528	0.00158	CcSEcCtD
Pimecrolimus—Diarrhoea—Methotrexate—muscle cancer	0.000528	0.00158	CcSEcCtD
Pimecrolimus—MTOR—Disease—HMGA1—muscle cancer	0.000506	0.00153	CbGpPWpGaD
Pimecrolimus—Hypersensitivity—Doxorubicin—muscle cancer	0.000493	0.00147	CcSEcCtD
Pimecrolimus—MTOR—Immune System—FOXO4—muscle cancer	0.000492	0.00149	CbGpPWpGaD
Pimecrolimus—Vomiting—Methotrexate—muscle cancer	0.000491	0.00147	CcSEcCtD
Pimecrolimus—Rash—Methotrexate—muscle cancer	0.000487	0.00145	CcSEcCtD
Pimecrolimus—Dermatitis—Methotrexate—muscle cancer	0.000486	0.00145	CcSEcCtD
Pimecrolimus—Headache—Methotrexate—muscle cancer	0.000484	0.00144	CcSEcCtD
Pimecrolimus—MTOR—Innate Immune System—KIT—muscle cancer	0.000475	0.00144	CbGpPWpGaD
Pimecrolimus—Pruritus—Doxorubicin—muscle cancer	0.000473	0.00141	CcSEcCtD
Pimecrolimus—Nausea—Methotrexate—muscle cancer	0.000459	0.00137	CcSEcCtD
Pimecrolimus—Diarrhoea—Doxorubicin—muscle cancer	0.000457	0.00137	CcSEcCtD
Pimecrolimus—MTOR—Adaptive Immune System—KIT—muscle cancer	0.000456	0.00138	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—KIT—muscle cancer	0.000454	0.00137	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—FOXO4—muscle cancer	0.000454	0.00137	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—IGF2—muscle cancer	0.000454	0.00137	CbGpPWpGaD
Pimecrolimus—Vomiting—Doxorubicin—muscle cancer	0.000425	0.00127	CcSEcCtD
Pimecrolimus—Rash—Doxorubicin—muscle cancer	0.000421	0.00126	CcSEcCtD
Pimecrolimus—Dermatitis—Doxorubicin—muscle cancer	0.000421	0.00126	CcSEcCtD
Pimecrolimus—Headache—Doxorubicin—muscle cancer	0.000419	0.00125	CcSEcCtD
Pimecrolimus—FKBP1A—Signaling Pathways—FOXO1—muscle cancer	0.000417	0.00126	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—TP53—muscle cancer	0.000401	0.00121	CbGpPWpGaD
Pimecrolimus—Nausea—Doxorubicin—muscle cancer	0.000397	0.00119	CcSEcCtD
Pimecrolimus—MTOR—Innate Immune System—MDM2—muscle cancer	0.000374	0.00113	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PTCH1—muscle cancer	0.00037	0.00112	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—FOXO1—muscle cancer	0.000363	0.0011	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—MDM2—muscle cancer	0.000359	0.00109	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—MDM2—muscle cancer	0.000358	0.00108	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—PTGS2—muscle cancer	0.000345	0.00104	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—FOXO1—muscle cancer	0.000335	0.00101	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—KIT—muscle cancer	0.000318	0.000962	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—FOXO4—muscle cancer	0.000318	0.000961	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CNR1—muscle cancer	0.000312	0.000943	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—KIT—muscle cancer	0.000277	0.000836	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—KIT—muscle cancer	0.000255	0.000772	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—IGF2—muscle cancer	0.000255	0.000771	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—MDM2—muscle cancer	0.00025	0.000757	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—FH—muscle cancer	0.00024	0.000726	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—FOXO1—muscle cancer	0.000235	0.00071	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—MDM2—muscle cancer	0.000218	0.000659	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—MDM2—muscle cancer	0.000201	0.000608	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PTGS2—muscle cancer	0.000194	0.000586	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—VEGFA—muscle cancer	0.00019	0.000575	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—KIT—muscle cancer	0.000179	0.000541	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—TP53—muscle cancer	0.000144	0.000435	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—MDM2—muscle cancer	0.000141	0.000426	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—MED12—muscle cancer	0.000136	0.00041	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ENO2—muscle cancer	0.000124	0.000374	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—VEGFA—muscle cancer	0.000107	0.000323	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—TP53—muscle cancer	8.08e-05	0.000244	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PTGS2—muscle cancer	4.31e-05	0.00013	CbGpPWpGaD
